Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease.

Although the primary endpoint, the changes in 10MWT time between baseline (Day 0) and Day 7, did not reach statistical significance (mean percent change in time − 3.5%, 95% CI − 10.8% to 3.7%; P = 0.32), a significant improvement was detected between baseline and Day 14 ( − 9.4%, 95% CI − 16.6% to − 2.2%; P = 0.01).

also in 111,027 other papers